Medicine developer CatSci has collaborated with the Cambridge Crystallographic Data Centre (CCDC). CatSci’s experimental expertise in material science combined with CCDC’s informatics tools will offer an integrated solution to customers, adding strategic value from molecule to medicine.
CCDC’s informatics-based services apply big data learnings from over one million published crystal structures to better understand solid forms, which will help to guide CatSci’s experimental screening.
Dr Robert Dennehy, Director of Crystallisation and Solid State and Scientific Advisory Board Member at CatSci, said: “Identifying the most stable polymorph and understanding the risks around hydration are essential for success when developing new medicines. The power of CCDC’s informatics tools will be used to validate the results of the focused experimental screens conducted here at CatSci. We believe that this coupling of experimental and in-silico approaches will significantly reduce the risk of a more stable polymorph or hydrate appearing in later development, and ultimately enhance the probability of small molecule success.”
Jonathan Betts, Director of Business Development at the CCDC, said: “Combining informatics insights from real world data with experimental results is a powerful way to get the fullest picture of a system of interest. Increasingly, the two approaches are used in complement to advance pharmaceutical development. By coupling CatSci’s experimental services with CCDC’s informatics services, researchers can access a more complete picture that ultimately advances more products to launch.”
